Mannatech Incorporated (MTEX)
MTEX trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1056358/000143774926012430/0001437749-26-012430-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MTEX on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001056358 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | TX |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $108.0M |
| Net income | -$15.2M |
| Operating income | -$426K |
| Net margin | -14.1% |
| Operating margin | -0.4% |
| Revenue growth | -8.3% |
| Cash | $6.2M |
| Total assets | $30.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions and events have raised substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $5.4M cash; operating cash flow -$51K a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,930,391 (2026-11-03); 1,900,930 a year earlier; 1,860,154 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-24 |
| Auditor | BDO USA, P.C., Dallas, Texas, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-10-23 |
| Late filings, 12 months | 2 NT notices | NT 10-K/A 2026-04-02 |
| Insider trades, 12 months | Bought $62K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $24.9M | $8.9M | -$249K | $5.4M | $2.8M | $103.1M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $26.6M | $1.0M | -$792K | $6.0M | $2.8M | $107.4M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $24.9M | $950K | $1.1M | $7.0M | $2.8M | $106.4M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $26.6M | -$11.3M | -$289K | $6.2M | $2.8M | $108.0M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $29.2M | $1.9M | $2.4M | $7.1M | $2.9M | $110.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $25.7M | -$4.3M | -$3.7M | Not filed | No debt tags | $113.0M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $26.6M | -$1.5M | -$1.4M | $9.3M | $2.9M | $115.0M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $29.0M | $2.3M | -$219K | $11.4M | $3.1M | $117.9M | 10-K 2026-04-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document S-3 REGISTRATION STATEMENT | S-3 | 2010-10-06 |
| Latest annual report FORM 10-K | 10-K | 2026-04-15 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -22.3% |
| 1 month | -16.7% |
| 3 months | +2.4% |
| Year to date | -23.6% |
| 1 year | -33.8% |
| From 52-week high | -36.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NAII | Natural Alternatives International Inc. | $0.9700 | +0.35% | $6.1M |
| BON | Bon Natural Life Limited | $1.09 | -0.91% | $8.9M |
| AKAN | Akanda Corp. Common Shares | $2.21 | +62.50% | $5.3M |
| BTMD | Biote Corp. | $0.9603 | -9.83% | $34.5M |
| IMCC | IM Cannabis Corp. Common Shares | $0.4950 | -12.76% | $913K |
| FTLF | FitLife Brands Inc. | $6.83 | -19.46% | $64.1M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier